FDA initiates pilot program for evaluating AI-designed drugs

Over 200 drugs developed using artificial intelligence are currently in clinical trials around the world. To date, none have received FDA approval.

The Food and Drug Administration has introduced a pilot initiative aimed at determining how to assess AI-generated evidence in drug applications. Ten companies have been selected for an accelerated, interactive review process.

Development in the AI pharmaceutical sector has progressed more rapidly than existing regulatory guidelines. This situation now defines the state of AI-driven dr